EDIT vs. PACB

Last updated Aug 1, 2026

EDIT (Editas Medicine, Inc.) and PACB (Pacific Biosciences of California, Inc.) are both stocks. Both are in the Healthcare sector — EDIT in Biotechnology, PACB in Diagnostics & Research. Over the past 10 years, EDIT returned -20.31%/yr vs -16.43%/yr for PACB. Their 0.42 correlation means their historical movements had little consistent relationship.

Performance

EDIT vs. PACB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, EDIT achieves a 25.85% return, which is significantly higher than PACB's -25.13% return. Over the past 10 years, EDIT has underperformed PACB with an annualized return of -20.31%, while PACB has yielded a comparatively higher -16.43% annualized return.

EDIT

• 1D: -4.09%
• 1M: -29.32%
• 6M: 29.65%
• YTD: 25.85%
• 1Y: 5.74%
• 3Y*: -33.19%
• 5Y*: -42.73%
• 10Y*: -20.31%
• ALL TIME*: -16.91%

PACB

• 1D: -5.41%
• 1M: -16.67%
• 6M: -38.05%
• YTD: -25.13%
• 1Y: 5.26%
• 3Y*: -52.83%
• 5Y*: -46.57%
• 10Y*: -16.43%
• ALL TIME*: -14.49%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
EDIT Editas Medicine, Inc.	$3.37M	$6.15M	$7.58M
PACB Pacific Biosciences of California, Inc.	$9.55M	$8.45M	$9.01M

EDIT vs. PACB - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EDIT Editas Medicine, Inc.	25.85%	61.42%	-87.46%	14.21%	-66.59%	-62.13%	136.78%	30.15%	-25.97%	89.34%
PACB Pacific Biosciences of California, Inc.	-25.13%	2.19%	-81.35%	19.93%	-60.02%	-21.13%	404.67%	-30.54%	180.30%	-30.53%

Correlation

The correlation between EDIT and PACB is 0.36, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.36
Correlation (3Y) Balances recent behavior with more history.	0.42
Correlation (5Y) Shows whether the relationship held over a longer period.	0.51
Correlation (10Y) Provides a long-term view across more market conditions.	0.43
Correlation (All Time) Calculated using the full available price history since Feb 3, 2016	0.42

The correlation between EDIT and PACB shifts across timeframes, from 0.36 (1 year) to 0.51 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap EDIT : $252.58M PACB : $434.84M
EPS EDIT : -$1.18 PACB : -$0.42
PS Ratio EDIT : 6.64 PACB : 2.65
PB Ratio EDIT : 57.29 PACB : 4.09
Total Revenue (TTM) EDIT : $35.86M PACB : $160.03M
Gross Profit (TTM) EDIT : $35.86M PACB : $59.34M
EBITDA (TTM) EDIT : -$76.66M PACB : -$146.34M

Return for Risk

EDIT vs. PACB — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

EDIT

EDIT Risk / Return Rank: 48
EDIT Sharpe Ratio Rank: 46
EDIT Sortino Ratio Rank: 53
EDIT Omega Ratio Rank: 50
EDIT Calmar Ratio Rank: 46
EDIT Martin Ratio Rank: 46

PACB

PACB Risk / Return Rank: 47
PACB Sharpe Ratio Rank: 45
PACB Sortino Ratio Rank: 51
PACB Omega Ratio Rank: 48
PACB Calmar Ratio Rank: 45
PACB Martin Ratio Rank: 45

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

EDIT vs. PACB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Pacific Biosciences of California, Inc. (PACB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	EDIT	PACB	Difference
Sharpe ratio: Return per unit of total volatility	0.03	0.02	+0.01
Sortino ratio: Return per unit of downside risk	0.76	0.68	+0.08
Omega ratio: Gain probability vs. loss probability	1.09	1.07	+0.01
Calmar ratio: Return relative to maximum drawdown	0.05	0.03	+0.02
Martin ratio: Return relative to average drawdown	0.08	0.04	+0.04

EDIT vs. PACB - Sharpe Ratio Comparison

The current EDIT Sharpe Ratio is 0.03, which is higher than the PACB Sharpe Ratio of 0.02. The chart below compares the historical Sharpe Ratios of EDIT and PACB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

EDIT vs. PACB - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, roughly equal to the maximum PACB drawdown of -98.22%. Use the drawdown chart below to compare losses from any high point for EDIT and PACB.

Drawdown Indicators

	EDIT	PACB	Difference
Max Drawdown Largest peak-to-trough decline	-98.92%	-98.22%	-0.70%
Max Drawdown (1Y) Largest decline over 1 year	-59.88%	-58.05%	-1.83%
Max Drawdown (3Y) Largest decline over 3 years	-91.18%	-92.53%	+1.35%
Max Drawdown (5Y) Largest decline over 5 years	-98.66%	-97.40%	-1.26%
Max Drawdown (10Y) Largest decline over 10 years	-98.92%	-98.22%	-0.70%
Current Drawdown Current decline from peak	-97.15%	-97.26%	+0.11%
Average Drawdown Average peak-to-trough decline	-63.06%	-70.75%	+7.69%
Ulcer Index Depth and duration of drawdowns from previous peaks	34.68%	33.29%	+1.39%

Volatility

EDIT vs. PACB - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 19.89% compared to Pacific Biosciences of California, Inc. (PACB) at 16.84%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than PACB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EDIT	PACB	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.89%	16.84%	+3.05%
Volatility (6M) Calculated over the trailing 6-month period	62.54%	54.98%	+7.56%
Volatility (1Y) Calculated over the trailing 1-year period	90.40%	85.57%	+4.83%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.71%	94.62%	-0.91%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.98%	84.90%	-0.92%

Dividends

EDIT vs. PACB - Dividend Comparison

Neither EDIT nor PACB has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both EDIT and PACB in my portfolio?

EDIT and PACB have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, EDIT or PACB?

EDIT has higher volatility (19.89%) compared to PACB (16.84%). In terms of maximum drawdown, EDIT dropped -98.92% vs PACB's -98.22%.

Which has better risk-adjusted returns?

EDIT currently has the higher Sharpe Ratio (0.03 vs 0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.